GW Pharmaceuticals Announces the Appointment of David Gryska to its Board of Directors
LONDON, Sept. 10, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines today announced the appointment of David Gryska to the Board of Directors. Mr. Gryska will also serve as a member of the Audit Committee. Mr. Gryska brings valuable global pharmaceutical and biotechnology industry experience and executive-level financial leadership to GW’s Board.
“I am very pleased to welcome David to our Board of Directors,” stated Dr. Geoffrey Guy, GW’s Founder and Chairman of the Board. “As a highly regarded leader in the biopharmaceutical industry, we look forward to benefiting from David’s wealth of experience as we continue to grow commercially and advance our pipeline with the goal of bringing breakthrough medicines to patients with significant unmet needs.”
“I am excited to be joining GW’s Board at a time of commercial growth and product pipeline expansion,” said Mr. Gryska. “GW has clearly established itself as the global leader in cannabinoid science, and I am excited at its prospects. I very much look forward to contributing to its future success.”
Mr. Gryska has years of experience as Chief Financial Officer at Incyte Corporation, Celgene Corporation, Scios, Inc., and Cardiac Pathways Corporation and is currently on the boards of Seattle Genetics, Inc., PDL BioPharma, Inc., and Aerie Pharmaceuticals, Inc. He brings to the Board valuable and relevant experience as a senior financial executive at life sciences and biotechnology companies engaged in financings, global expansion and other strategic transactions. He also has extensive knwledge of accounting principles and financial reporting rules and regulations, tax compliance and oversight of the financial reporting processes of several large, publicly traded corporations.
About GW Pharmaceuticals plc and Greenwich Biosciences, Inc.